Three cases revealed BRAF V600E mutation may be the mechanism for acquired crizotinib resistance after ROS1 rearrangement in NSCLC, two of them had acquired ROS1 rearrangement co-existing with BRAF V600E (35, 36). Here, ROS1 is linked to non-small cell lung carcinoma.